Associations - BRAF mutation

BRAF mutation BRAF mutation	Melanoma Melanoma	dabrafenib + granisetron intravenous Sensitive: A2 - Guideline
BRAF mutation BRAF mutation	Colorectal Cancer CRC	ramucirumab Sensitive: B - Late Trials
BRAF mutation BRAF mutation	Colorectal Cancer CRC	ziv-aflibercept IV Sensitive: B - Late Trials
BRAF mutation BRAF mutation	Colorectal Cancer CRC	bevacizumab Sensitive: B - Late Trials
BRAF mutation BRAF mutation	Colorectal Cancer CRC	cetuximab Resistant: B - Late Trials
BRAF mutation BRAF mutation	Colorectal Cancer CRC	regorafenib Sensitive: B - Late Trials
BRAF mutation BRAF mutation	Melanoma Melanoma	nivolumab + ipilimumab Sensitive: B - Late Trials
BRAF mutation BRAF mutation	Colorectal Cancer CRC	FOLFIRI + cetuximab Sensitive: B - Late Trials
BRAF mutation BRAF mutation	Acute Myelogenous Leukemia AML	gilteritinib Resistant: B - Late Trials
BRAF mutation BRAF mutation	Melanoma Melanoma	PD-L1 inhibitor Sensitive: B - Late Trials
BRAF mutation BRAF mutation	Melanoma Melanoma	ipilimumab Sensitive: B - Late Trials
BRAF mutation BRAF mutation	Colorectal Cancer CRC	panitumumab Sensitive: C2 – Inclusion Criteria
BRAF mutation BRAF mutation	Melanoma Melanoma	encorafenib + binimetinib Sensitive: C2 – Inclusion Criteria
BRAF mutation BRAF mutation	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	selumetinib Sensitive: C2 – Inclusion Criteria
BRAF mutation BRAF mutation	Melanoma Melanoma	BVD-523 Sensitive: C2 – Inclusion Criteria
BRAF mutation BRAF mutation	Melanoma Melanoma	trametinib Sensitive: C2 – Inclusion Criteria
BRAF mutation BRAF mutation	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	trametinib + dabrafenib Sensitive: C2 – Inclusion Criteria
BRAF mutation BRAF mutation	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	atezolizumab + cobimetinib Sensitive: C2 – Inclusion Criteria
BRAF mutation BRAF mutation	Colon Cancer Colon Cancer	bevacizumab Sensitive: C2 – Inclusion Criteria
BRAF mutation BRAF mutation	Melanoma Melanoma	selumetinib Sensitive: C2 – Inclusion Criteria
BRAF mutation BRAF mutation	Melanoma Melanoma	nivolumab + trametinib + dabrafenib Sensitive: C2 – Inclusion Criteria
BRAF mutation BRAF mutation	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	vemurafenib Sensitive: C2 – Inclusion Criteria
BRAF mutation BRAF mutation	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Non Small Cell Lung Cancer NSCLC	PD1 inhibitor Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Melanoma Melanoma	Immunotherapy Resistant: C3 – Early Trials
BRAF mutation BRAF mutation	Ovarian Cancer Ovarian Cancer	PLX8394 Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Mucosal Melanoma Mucosal Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Melanoma Melanoma	dabrafenib + KRT-232 Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Melanoma Melanoma	trametinib + dabrafenib + durvalumab Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Melanoma Melanoma	AS703026 Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Solid Tumor Solid Tumor	Immunotherapy Resistant: C3 – Early Trials
BRAF mutation BRAF mutation	Multiple Myeloma Multiple Myeloma	venetoclax + cobimetinib Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Ovarian Cancer Ovarian Cancer	vemurafenib + sorafenib Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Melanoma Melanoma	crizotinib + vemurafenib Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Melanoma Melanoma	PLX8394 + cobicistat Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Colorectal Cancer CRC	PLX8394 + cobicistat Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	PLX8394 + cobicistat Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	PLX8394 + cobicistat Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Glioma Glioma	PLX8394 + cobicistat Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Melanoma Melanoma	BRAF inhibitor Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Cutaneous Melanoma Cutaneous Melanoma	PD1 inhibitor Resistant: C3 – Early Trials
BRAF mutation BRAF mutation	Colorectal Cancer CRC	EGFR inhibitor Resistant: C3 – Early Trials
BRAF mutation BRAF mutation	Ovarian Cancer Ovarian Cancer	VS-6766 Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Melanoma Melanoma	dabrafenib + SNR1611 Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Melanoma Melanoma	trametinib + KRT-232 Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Melanoma Melanoma	selumetinib + RTB101 Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Melanoma Melanoma	DAY101 Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	dabrafenib Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	vemurafenib + atezolizumab Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Colorectal Cancer CRC	cetuximab + selumetinib Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Multiple Myeloma Multiple Myeloma	MEK inhibitor Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Melanoma Melanoma	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Melanoma Melanoma	BRAF inhibitor + MEK inhibitor Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Mucosal Melanoma Mucosal Melanoma	cisplatin + dacarbazine Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Non Small Cell Lung Cancer NSCLC	trametinib + dabrafenib Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Mucosal Melanoma Mucosal Melanoma	cisplatin + temozolomide Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Non Small Cell Lung Cancer NSCLC	durvalumab Resistant: C3 – Early Trials
BRAF mutation BRAF mutation	Melanoma Melanoma	PD1 inhibitor + CTLA4 inhibitor Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Prostate Cancer Prostate Cancer	enzalutamide Resistant: C3 – Early Trials
BRAF mutation BRAF mutation	Melanoma Melanoma	EOS884448 Sensitive: C4 – Case Studies
BRAF mutation BRAF mutation	Lung Adenocarcinoma LUAD	crizotinib + vemurafenib Sensitive: C4 – Case Studies
BRAF mutation BRAF mutation	Cutaneous Melanoma Cutaneous Melanoma	BRAF inhibitor Resistant: C4 – Case Studies
BRAF mutation BRAF mutation	Cutaneous Melanoma Cutaneous Melanoma	BRAF inhibitor + MEK inhibitor Sensitive: C4 – Case Studies
BRAF mutation BRAF mutation	Cholangiocarcinoma Cholangiocarcinoma	LTT462 Sensitive: C4 – Case Studies
BRAF mutation BRAF mutation	Cholangiocarcinoma Cholangiocarcinoma	BRAF inhibitor Sensitive: C4 – Case Studies
BRAF mutation BRAF mutation	Renal Cell Carcinoma RCC	vemurafenib Sensitive: C4 – Case Studies
BRAF mutation BRAF mutation	Colorectal Cancer CRC	trametinib + dabrafenib + panitumumab Resistant: C4 – Case Studies
BRAF mutation BRAF mutation	Anaplastic Astrocytoma Anaplastic Astrocytoma	dabrafenib Sensitive: C4 – Case Studies
BRAF mutation BRAF mutation	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	dabrafenib + SCH772984 Sensitive: D – Preclinical
BRAF mutation BRAF mutation	Melanoma Melanoma	ARN22089 Sensitive: D – Preclinical
BRAF mutation BRAF mutation	Breast Cancer Breast Cancer	TAK-228 Sensitive: D – Preclinical
BRAF mutation BRAF mutation	Colorectal Cancer CRC	PLX4720 Sensitive: D – Preclinical
BRAF mutation BRAF mutation	Pancreatic Cancer Pancreatic Cancer	SCH772984 Sensitive: D – Preclinical
BRAF mutation BRAF mutation	Melanoma Melanoma	SCH772984 Sensitive: D – Preclinical
BRAF mutation BRAF mutation	Melanoma Melanoma	PLX4720 Sensitive: D – Preclinical
BRAF mutation BRAF mutation	Non Small Cell Lung Cancer NSCLC	LY3009120 Sensitive: D – Preclinical
BRAF mutation BRAF mutation	Colorectal Cancer CRC	SY-5609 Sensitive: D – Preclinical
BRAF mutation BRAF mutation	Colorectal Cancer CRC	ABT 263 + AZD8055 Sensitive: D – Preclinical
BRAF mutation BRAF mutation	Ovarian Cancer Ovarian Cancer	CI-1040 Sensitive: D – Preclinical
BRAF mutation BRAF mutation	Melanoma Melanoma	vemurafenib + dabrafenib + encorafenib Sensitive: D – Preclinical
BRAF mutation BRAF mutation	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	SU6656 Sensitive: D – Preclinical
BRAF mutation BRAF mutation	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	PP2 Sensitive: D – Preclinical
BRAF mutation BRAF mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	RTB101 + RAF265 Sensitive: D – Preclinical
BRAF mutation BRAF mutation	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	HM95573 Sensitive: D – Preclinical
BRAF mutation BRAF mutation	Melanoma Melanoma	RTB101 Sensitive: D – Preclinical
BRAF mutation BRAF mutation	Pancreatic Cancer Pancreatic Cancer	vemurafenib Sensitive: D – Preclinical
BRAF mutation BRAF mutation	Melanoma Melanoma	MEK inhibitor + TA99 Sensitive: D – Preclinical